Analysis of drug combinations with the PKC inhibitor IDE196 support dual MEK and PKC inhibition as a rational combination in metastatic uveal melanoma

被引：3
|
作者：
Frey, Christian R. [1 ]
Wagle, Marie-Claire [1 ]
Vaidya, Kedar [1 ]
Hambleton, Julie [1 ]
Lackner, Mark [1 ]
Mounir, Zineb [1 ]
机构：
[1] Ideaya Biosci, San Francisco, CA USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-5337
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5337
引用
收藏
页数：2
相关论文
共 10 条
  • [1] Combined PKC and MEK inhibition for treating metastatic uveal melanoma
    Sagoo, M. S.
    Harbour, J. W.
    Stebbing, J.
    Bowcock, A. M.
    [J]. ONCOGENE, 2014, 33 (39) : 4722 - 4723
  • [2] Combined PKC and MEK inhibition for treating metastatic uveal melanoma
    M S Sagoo
    J W Harbour
    J Stebbing
    A M Bowcock
    [J]. Oncogene, 2014, 33 : 4722 - 4723
  • [3] Preclinical evaluation of a PKC and MET inhibitor combination in metastatic uveal melanoma.
    Wagle, Marie-Claire
    Ravindran, Nandini
    Pankajakshan, Divya
    Lackner, Mark
    Mounir, Zineb
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [4] A Phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma
    Kapiteijn, Ellen
    Carlino, Matteo
    Boni, Valentina
    Loirat, Delphine
    Speetjens, Frank
    Park, John
    Calvo, Emiliano
    Carvajal, Richard
    Nyakas, Marta
    Gonzalez-Maffe, Juan
    Zhu, Xu
    Thiruvamoor, Ramu
    Yerramilli-Rao, Padmaja
    Piperno-Neumann, Sophie
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [5] FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
    Tarin, Malcy
    Nemati, Fariba
    Decaudin, Didier
    Canbezdi, Christine
    Marande, Benjamin
    Silva, Lisseth
    Derrien, Heloise
    Jochemsen, Aart G.
    Gardrat, Sophie
    Piperno-Neumann, Sophie
    Rodrigues, Manuel
    Mariani, Pascale
    Cassoux, Nathalie
    Stern, Marc-Henri
    Roman-Roman, Sergio
    Alsafadi, Samar
    [J]. CANCERS, 2023, 15 (08)
  • [6] A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma
    Bauer, Sebastian
    Larkin, James
    Hodi, F. Stephen
    Stephen, Frank
    Kapiteijn, Ellen H. W.
    Schwartz, Gary K. K.
    Calvo, Emilano
    Yerramilli-Rao, Padmaja
    Piperno-Neumann, Sophie
    Carvajal, Richard D. D.
    [J]. FRONTIERS IN ONCOLOGY, 2023, 12
  • [7] Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma
    Visser, Michael
    Papillon, Julien P. N.
    Luzzio, Michael
    Lamarche, Matthew J.
    Fan, Jianmei
    Michael, Walter
    Wang, David
    Zhang, Alan
    Straub, Christopher
    Mathieu, Simon
    Kato, Mitsunori
    Palermo, Mark
    Chen, Christine
    Ramsey, Timothy
    Joud, Carol
    Barrett, Rosemary
    Vattay, Anthony
    Guo, Ribo
    Bric, Anka
    Chung, Franklin
    Liang, Guiqing
    Romanowski, Michael J.
    Lam, Joni
    Thohan, Sanjeev
    Atassi, Faraj
    Wylie, Andrew
    Cooke, Vesselina G.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (02) : 1447 - 1459
  • [8] A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
    S. Piperno-Neumann
    M. S. Carlino
    V. Boni
    D. Loirat
    F. M. Speetjens
    J. J. Park
    E. Calvo
    R. D. Carvajal
    M. Nyakas
    J. Gonzalez-Maffe
    X. Zhu
    M. D. Shirley
    T. Ramkumar
    A. Fessehatsion
    H. E. Burks
    P. Yerramilli-Rao
    E. Kapiteijn
    [J]. British Journal of Cancer, 2023, 128 : 1040 - 1051
  • [9] A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
    Piperno-Neumann, S.
    Carlino, M. S.
    Boni, V.
    Loirat, D.
    Speetjens, F. M.
    Park, J. J.
    Calvo, E.
    Carvajal, R. D.
    Nyakas, M.
    Gonzalez-Maffe, J.
    Zhu, X.
    Shirley, M. D.
    Ramkumar, T.
    Fessehatsion, A.
    Burks, H. E.
    Yerramilli-Rao, P.
    Kapiteijn, E.
    [J]. BRITISH JOURNAL OF CANCER, 2023, 128 (06) : 1040 - 1051
  • [10] PHARMACOKINETIC CHARACTERIZATION AND PRELIMINARY EXPOSURE-SAFETY/RESPONSE ANALYSIS OF A NOVEL PKC INHIBITOR LXS196 IN A PHASE I STUDY IN METASTATIC UVEAL MELANOMA PATIENTS.
    Zhu, X.
    Roy, M.
    Gonzalez-Maffe, J.
    Yerramilli-Rao, P.
    Burks, H.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S78 - S78
1